Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I acute myocardial infarction (AMI) PROTECT registry
Main finding · CI-AKIResult — go to the resultOdds ratio 0.356 95% CI 0.134–0.943Authors' conclusion
In T2DM patients with AMI, the use of SGLT2-I was associated with a lower risk of CI-AKI, mostly in patients without CKD.
Study context
- Population
- Patients with T2DM and AMI undergoing PCI, 2018–2021, stratified by chronic kidney disease (CKD); median age 70 [61–79] years
- Participants
- 646 patients
- Exposure
- SGLT2-I users vs non-SGLT2-I users
- SGLT2-In = 111
- Non-SGLT2-In = 535reference
- Outcome
- Contrast-induced acute kidney injury (CI-AKI)
Methodological detailsmulticenter, international, consecutive patients
- Multicenter
- International
- Consecutive patients
Main finding
CI-AKI
Odds ratio
0.356
95% CI 0.134–0.943
P = 0.038
By group
SGLT2-Ivs Non-SGLT2-I
OR 0.356 (95% CI 0.134–0.943); P = 0.038
As reported in the abstract
- Overall contrast-induced acute kidney injury (CI-AKI)
- 76 (11.8%)
Observational data: associations, not effects.
Further findings
| Outcome | P value |
|---|---|
| CI-AKI in patients without CKDLower with SGLT2-I | P = 0.040 |
Creatinine 72 h after PCI
- Significantly lower creatinine with SGLT2-I in both non-CKD and CKD strata
Creatinine at discharge in CKD cohort
- SGLT2-I users maintained significantly lower creatinine at discharge
Original publication
Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry. Diabetes Res Clin Pract. Published 3 June 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →